CCL23 Protein (AA 46-120)

Catalog No. ABIN2666897

This Recombinant CCL23 protein is expressed in Escherichia coli (E. coli).

Quick Overview for CCL23 Protein (AA 46-120) (ABIN2666897)

Target: CCL23 (Chemokine (C-C Motif) Ligand 23 (CCL23))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 46-120

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its property to chemoattract THP-1 cells in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CCL23 (Chemokine (C-C Motif) Ligand 23 (CCL23))

Alternative Name: CCL23

Background: Human CCL23 was initially identified in a cDNA library derived from human endothelial cells. CCL23 has six cysteine residues and posseses a separately encoded amino-terminal domain, characteristic of similar chemokines CCL6, CCL9, and CCL15. These four chemokines are weak agonists for CCR1, nevertheless, they can be proteolytically cleaved in the amino-terminus, resulting in forms with higher chemoattractant activity. Thus, NH2-terminus truncated forms of CCL23 have been detected in synovial fluid of patients with rheumatoid arthritis (RA). In vitro studies have shown that CCL23 can be processed by MMPs at the amino and carboxyl terminus. CCL23 (26-99) is the predominant stable form after using MMP1, 2, 3, 7, 8, or 12. CCL23 (30-99) is formed by MMP14, elastase, and proteolytic activity in arthritic synovial fluid. In addition, CCL23 has been detected in serum of patients with active RA, in conjunction with CXCL13, TNFSR9, M-CSF, and TNFα. High levels in serum of these cytokines correlate with joint inflammation and have been considered as biomarkers of active RA. Also, high levels of CCL23 have been detected in plasma of atherosclerotic patients. High expression of CCL23 has been found in skin of atopic dermatitis patients, and in mucosal epithelial cells and inflammatory cells in sinonasal tissues of patients with chronic rhinosinusitis (CRS).

Molecular Weight: The 75 amino acid recombinant protein has a predicted molecular mass of approximately 8.5 kDa. The DTT-reduced and non-reduced protein migrate at approximately 12 and 14 kDa by SDS-PAGE respectively. The N-terminal amino acid is Arg.